On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-Mﾙ adjuvant. The submission to WHO was based on the companies’ previous regulatory submission to the Drugs Controller General of India.